



Date: **July 23, 2024**

Federal Communications Commission  
Authorization and Evaluation Division  
7435 Oakland Mills Road  
Columbia, MD 21046-1609

SUBJECT: **End Product Model Difference Attestation**

**FCC ID: 2AYCW-MALLYANN**

**Brand/Trade Name: Mallya ( Mallya<sup>D</sup> and Mallya<sup>G</sup>)**

**Model Number: EFA2 / CND1**

We, **BIOCORP**, hereby declare that our end product, , **Mallya** includes **EFA2 / CND1** as listed above. The intention of these models is only for that the model CND1 is for the pens Novo Nordisk for diabetes therapeutic area and the model EFA2 is for the pens Novo Nordisk for growth disorder area.

Should you have any question, feel free to contact me directly.

Sincerely yours,

-----  
Alexia GARIN  
+33 +33645620362  
agarin@biocorp.fr